BCDA BioCardia Inc: Year-over-year earnings per share growth for the last twelve months

Graphic logo of BioCardia, Inc (BCDA)

The quarterly EPS dynamics illustrate the financial trajectory of BioCardia, Inc. (BCDA). The value 67.60 captures the current magnitude of this indicator. BioCardia, Inc. is recognized as a leader in myocardial regeneration, leveraging the body's internal reserves to combat heart failure. Developments include AI systems and robotics for the precise administration of cellular therapies. The strategy excludes mergers, relying solely on alliances with leading research centers.

biocardia.com (BCDA) - Year-over-year earnings per share growth for the last 12 months from 07/04/2022 to 11/10/2026

BCDA (BioCardia Inc): analytical breakdowns and indicator data

- share price and expert price forecast:
Stock Price BioCardia|BCDA - Analyst Consensus Forecast
- company stock capitalization data:
Market Value BioCardia, Inc|BCDA - Value Adjusted for Debt and Cash
- book capitalization data:
Book Value per Share BioCardia|BCDA - Accounting Capitalization|Market Capitalization to Book Value Ratio biocardia.com|BCDA - Company Total Asset Base
- business debt structure and liquidity details:
Total Debt to Capital BioCardia, Inc.|BCDA - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio BioCardia, Inc.|BCDA - Aggregate Debt Obligations|Debts to Book Capitalization BioCardia, Inc|BCDA - Long-Term Debt Volume|Company Short-Term Debt BioCardia|Quick Ratio biocardia.com
- earnings and valuation multiples indicators:
BCDA - Net Income|Future Profit BioCardia, Inc.|BCDA - Business Payback Period|Forward P/E Multiple BioCardia, Inc|BCDA - Price/Earnings to Growth Ratio|EV/EBITDA Multiple BioCardia, Inc|BCDA - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) BioCardia|BCDA - Earnings per share for the last 12 months|Quarterly EPS earnings growth biocardia.com|BCDA - Earnings growth in current year|Earnings growth forecast for next year BioCardia, Inc.
Summary company analytics:BioCardia - BCDA
Flagship merchandise of biocardia.com

The success of BioCardia, Inc. (BCDA) correlates directly with the results of late-stage cardiology therapy trials amid high R&D expenditures. By analyzing the quarterly EPS increase of 67.60, we assess the net profit per share dynamics, which allows us to distinguish real fundamental business growth from temporary speculative momentum and avoid overpaying for the asset.

Competitors of BioCardia, Inc. (BCDA)

REGN: Quarterly EPS earnings growth|iRhythm Technologies, Inc. (IRTC) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months Lantheus Medical Imaging|MLYS: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth HTFL|kestramedical.com - Year-over-year earnings per share growth for the last 12 months|Quarterly EPS earnings growth ESPR (Esperion)|Year-over-year net earnings per share change for the last twelve months Amarin Corporation (AMRN)|Anteris Technologies Ltd - Quarterly EPS earnings growth|TNYA - Quarterly EPS earnings growth|CVRX (CVRx, Inc.) - Year-over-year net earnings per share growth for the last 12 months|milestonepharma.com - Year-over-year earnings per one share growth for the last 12 months|CRDL (Cardiol Therapeutics Inc) - Quarterly EPS earnings growth|HeartBeam Inc (BEAT) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Tenax Therapeutics, Inc (TENX)|Adagio Medical, Inc. - Year-over-year earnings per share growth for the last 12 months|Quarterly EPS earnings growth VTAK (Catheter Precision)|ABIO - Year-over-year net earnings per share growth for the last 12 months|ACST: Year-over-year net earnings per share growth for the last 12 months|Year-over-year net earnings per share change for the last twelve months Aerovate Therapeutics Inc. AVTE|VERV: Quarterly EPS earnings growth|WINT (Windtree Therapeutics, Inc.) - Year-over-year earnings per share growth for the last twelve months